Gastroretentive Drug Delivery Systems Outsourcing Market Report 2026

The gastroretentive drug delivery systems outsourcing market size has grown strongly in recent years. It will grow from $1.49 billion in 2025 to $1.61 billion in 2026 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to limitations of conventional oral drug delivery, growth in cro services, need for improved drug absorption, pharmaceutical pipeline expansion, formulation technology advancements.

The gastroretentive drug delivery systems outsourcing market size is expected to see strong growth in the next few years. It will grow to $2.1 billion in 2030 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to increasing complex drug molecules, demand for patient-centric delivery systems, expansion of outsourcing strategies, innovation in gastroretentive technologies, cost optimization by pharma companies. Major trends in the forecast period include growing outsourcing of advanced drug delivery development, increased demand for prolonged gi retention formulations, rising adoption of floating drug delivery systems, expansion of cro partnerships in formulation development, focus on enhanced drug bioavailability.

The rising prevalence of gastrointestinal disorders is expected to drive the growth of the gastroretentive drug delivery systems outsourcing market in the coming years. Gastrointestinal disorders encompass a wide range of diseases affecting the digestive tract, including the stomach, liver, gallbladder, intestines, and pancreas. Factors such as aging populations, antibiotic use, infections, dietary changes, stress, lifestyle habits, and obesity are contributing to the increasing incidence of these disorders. Outsourcing gastroretentive drug delivery systems provides pharmaceutical companies with the expertise and resources needed to address the growing burden of gastrointestinal disorders, ultimately improving patient outcomes and quality of life. For example, in August 2023, the National Institute of Diabetes and Digestive and Kidney Diseases, a US-based government-funded research institute, reported that 60 to 70 million people are affected by digestive diseases. Therefore, the rising prevalence of gastrointestinal disorders is propelling the gastroretentive drug delivery systems outsourcing market.

The growing prevalence of age-related disorders is also expected to support the expansion of the gastroretentive drug delivery systems market. Age-related disorders include a broad range of medical conditions and functional impairments that predominantly affect older adults, such as cardiovascular diseases, neurodegenerative disorders, musculoskeletal conditions, and sensory impairments. These disorders are increasing due to aging populations, longer life expectancy, lifestyle factors, and the accumulation of chronic conditions. For instance, in April 2025, the Centers for Disease Control and Prevention, a US-based public health agency, reported that in 2023 approximately 194 million American adults - comprising 6 in 10 young adults, 8 in 10 midlife adults, and 9 in 10 older adults - reported having one or more chronic conditions. The prevalence of chronic conditions rose by 7 percentage points among young adults. Consequently, the increasing prevalence of age-related disorders is driving the gastroretentive drug delivery systems outsourcing market.

Key companies in the gastroretentive drug delivery systems outsourcing market are focusing on developing innovative products, such as ready-to-fill (RTF) colon functional capsules, to improve drug delivery efficiency and enhance patient convenience. Ready-to-fill (RTF) colon functional capsules are pre-manufactured, empty capsules designed to be filled with specific formulations or active ingredients targeted to the colon. For example, in September 2024, Evonik, a Germany-based advanced drug delivery provider, launched EUDRACAP colon functional capsules, designed for targeted oral drug delivery to the ileo-colonic region. These innovative capsules are the first ready-to-fill option available in the market, intended for sensitive active ingredients such as live biotherapeutic products (LBPs). Currently offered in technical grade, a GMP-grade version is also under development. EUDRACAP colon capsules simplify formulation, accelerate time to market, and enhance the oral drug development process, representing a significant advancement in gastroretentive drug delivery systems.

Major companies operating in the gastroretentive drug delivery systems outsourcing market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., AstraZeneca plc, Novartis AG, Evonik Industries AG, SGS SA, Lonza Group AG, Sun Pharmaceutical Industries Ltd., Catalent Inc., AptarGroup Inc., Cadila Pharmaceuticals, Ashland Global Holdings Inc, Lupin Limited, Torrent Pharmaceuticals Ltd., Evotec SE, Colorcon Inc., Quotient Sciences Limited, Aenova Group, Vectura Group Ltd., Coating Place Inc., Xiromed LLC, SPI Pharma Inc.

North America was the largest region in the gastroretentive drug delivery systems outsourcing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroretentive drug delivery systems outsourcing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gastroretentive drug delivery systems outsourcing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the gastroretentive drug delivery systems outsourcing market by increasing costs of imported excipients, polymers, and manufacturing equipment. CROs and pharmaceutical companies in developed regions are most affected due to reliance on imported formulation materials. These tariffs raise development costs but encourage regional sourcing and local manufacturing capabilities.

The gastroretentive drug delivery systems outsourcing market research report is one of a series of new reports that provides gastroretentive drug delivery systems outsourcing market statistics, including gastroretentive drug delivery systems outsourcing industry global market size, regional shares, competitors with a gastroretentive drug delivery systems outsourcing market share, detailed gastroretentive drug delivery systems outsourcing market segments, market trends and opportunities, and any further data you may need to thrive in the gastroretentive drug delivery systems outsourcing industry. This gastroretentive drug delivery systems outsourcing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Gastroretentive drug delivery systems outsourcing refers to the practice in which pharmaceutical companies partner with external service providers or contract research organizations (CROs) to develop and manufacture drug delivery systems that extend the residence time of medications in the gastrointestinal (GI) tract. These systems are designed to enhance drug absorption, improve therapeutic effectiveness, and optimize patient outcomes.

The main types of gastroretentive drug delivery systems outsourcing include floating systems, bioadhesive systems, and other types. A floating drug delivery system (FDDS) is a type of system created to prolong the retention of drugs in the stomach and upper gastrointestinal tract. The dosage forms include tablets, liquids, microspheres, capsules, and others, and are applied for conditions such as gastroesophageal reflux disease (GERD), neurological disorders, and other applications. These systems are utilized by various end-users, including pharmaceutical companies, contract research organizations (CROs), and others.

The gastroretentive drug delivery systems outsourcing market consists of revenues earned by entities by providing services such as formulation development, analytical and testing services, quality assurance and control, and clinical trial services. The market value includes the value of related goods sold by the service provider or included within the service offering. The gastroretentive drug delivery systems outsourcing market also includes sales of bioadhesive systems, swelling systems, and high-density systems, and floating systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.